CDA-AMC suggests reimbursement of venetoclax plus ibrutinib for select patients with mantle cell lymphoma, indicating careful eligibility criteria.
Canada’s Drug Agency (CDA-AMC) recommends that Venclexta, in combination with ibrutinib (Venclexta plus ibrutinib), be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) if certain conditions are met. Venclexta should only be covered for adults who are in relatively good health and have already tried at least 1 other treatment for this disease. Venclexta should only be reimbursed if it is prescribed by clinicians with expertise in managing MCL and monitoring therapy, and the cost of Venclexta is reduced.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: